MGMT and glioblastoma: CORE is a Phase 2 clinical trial in newly diagnosed glioblastoma in subjects with an unmethylated O6‐methylguanine‐deoxyribonucleic acid methyltransferase (MGMT) gene promoter in the tumor tissue.